Color Logo.png
Structural Heart Devices Market will grow to USD 31.7 billion by 2030 : GreyViews
27 janv. 2023 15h00 HE | GreyViews
Pune India, Jan. 27, 2023 (GLOBE NEWSWIRE) -- The market has been studied for the below mentioned-segmentation and regional analysis for North America, Europe, Asia, South America, and the Middle...
biosig_rgb.png
BioSig Issues Shareholder Update to Highlight Recent Achievements and Ongoing Developments
19 janv. 2023 08h30 HE | BioSig Technologies, Inc.
Westport, CT, Jan. 19, 2023 (GLOBE NEWSWIRE) -- To date, the Company's FDA 510(k)-cleared PURE EP™ System has been used in approximately 3,000 patient cases across the United States The...
biosig_rgb.png
Update: BioSig’s PURE EP™ System Demonstrates Potential Time and Cost Savings at the 15th APHRS Scientific Session in Singapore
14 déc. 2022 16h30 HE | BioSig Technologies, Inc.
Westport, CT, Dec. 14, 2022 (GLOBE NEWSWIRE) -- - BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering...
biosig_rgb.png
BioSig’s PURE EP™ System Demonstrates Potential Time and Cost Savings at the 15th APHRS Scientific Session in Singapore
14 déc. 2022 08h00 HE | BioSig Technologies, Inc.
Westport, CT, Dec. 14, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering...
avicorelogo.png
Avricore Health Reports Third-Quarter 2022 Results
29 nov. 2022 11h08 HE | Avricore Health Inc.
VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) today released its Q3 results which demonstrate significant revenue growth,...
InCarda Logo.png
Final Results from Phase 2 INSTANT Trial of InRhythm™ for the Treatment of Newly Diagnosed and Recurrent Paroxysmal Atrial Fibrillation Presented at 2022 American Heart Association Scientific Sessions
07 nov. 2022 07h00 HE | InCarda Therapeutics, Inc.
Data Demonstrate Orally Inhaled Flecainide May Provide a Safe, Effective, and Convenient First-Line Treatment Option for Cardioversion of Recent-Onset Newly Diagnosed and Paroxysmal Atrial...
Bio-Sig-Logo-horiz.jpg
BioSig Signs Master Research Agreement with Cleveland Clinic to Explore Expanded Applications for its Digital Signal Processing Technology
24 oct. 2022 11h03 HE | BioSig Technologies, Inc.
Westport, CT, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Medical Center of Excellence to leverage the Company’s PURE EP™ System to further its research and educational objectives as a leader in cardiac...
Bio-Sig-Logo-horiz.jpg
BioSig Invited to Attend and Sponsor Venice Arrhythmias 2022
12 oct. 2022 10h00 HE | BioSig Technologies, Inc.
Westport, CT, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented...
TIP_link_300x300.jpg
$4.5+ Billion Artificial Heart Market Size to Exhibit CAGR of 15+% by 2028, Deep Dive Analysis of Key Players and Growth Opportunities
12 oct. 2022 09h16 HE | The Insight Partners
New York, Oct. 12, 2022 (GLOBE NEWSWIRE) -- The Insight Partners recently published a report on "Artificial Heart Market Size, Share, Trends, Growth Strategy and Forecast to 2028 – COVID-19 Impact...
Bio-Sig-Logo-horiz.jpg
BioSig Executes Purchase Agreement with Methodist Hospital, San Antonio and Expands Customer Base
07 oct. 2022 09h35 HE | BioSig Technologies, Inc.
Westport, CT, Oct. 07, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented...